Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes

SUMMARY Extrinsic signals are implicated in breast cancer resistance to HER2-targeted tyrosine kinase inhibitors (TKIs). To examine how microenvironmental signals influence resistance, we monitored TKI-treated breast cancer cell lines grown on microenvironment microarrays composed of printed extracellular matrix proteins supplemented with soluble proteins. We tested ~2,500 combinations of 56 soluble and 46 matrix microenvironmental proteins on basal-like HER2+ (HER2E) or luminal-like HER2+ (L-HER2+) cells treated with the TKIs lapatinib or neratinib. In HER2E cells, hepatocyte growth factor, a ligand for MET, induced resistance that could be reversed with crizotinib, an inhibitor of MET. In L-HER2+ cells, neuregulin1-β1 (NRG1β), a ligand for HER3, induced resistance that could be reversed with pertuzumab, an inhibitor of HER2-HER3 heterodimerization. The subtype-specific responses were also observed in 3D cultures and murine xenografts. These results, along with bioinformatic pathway analysis and siRNA knockdown experiments, suggest different mechanisms of resistance specific to each HER2+ subtype: MET signaling for HER2E and HER2-HER3 heterodimerization for L-HER2+ cells.

[1]  Gordon B Mills,et al.  Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. , 2012, Cancer cell.

[2]  J. Baselga,et al.  Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[3]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[4]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[5]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[6]  Yoshikazu Ohta,et al.  Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein , 2011, The Journal of Biological Chemistry.

[7]  Dhara N. Amin,et al.  Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver , 2010, Science Translational Medicine.

[8]  Anne E Carpenter,et al.  Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software , 2011, Bioinform..

[9]  Jayanta Debnath,et al.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.

[10]  Harvard Medical School,et al.  Targeting androgen receptor in estrogen receptor-negative breast cancer. , 2011, Cancer cell.

[11]  O. Ortmann,et al.  Modular anti‐EGFR and anti‐Her2 targeting of SK‐BR‐3 and BT474 breast cancer cell lines in the presence of ErbB receptor‐specific growth factors , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[12]  Laura M. Heiser,et al.  A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047 , 2009, BMC medicine.

[13]  H. Gómez,et al.  Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[15]  A. Harris,et al.  Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer , 2015, Oncotarget.

[16]  R. Ball,et al.  Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients. , 1996, British Journal of Cancer.

[17]  Laura M. Heiser,et al.  Modeling precision treatment of breast cancer , 2013, Genome Biology.

[18]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[19]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[20]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[21]  Catherine C. Park,et al.  Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. , 2015, Integrative biology : quantitative biosciences from nano to macro.

[22]  Saeed Sadeghi,et al.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Landgraf,et al.  Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling , 2012, Proceedings of the National Academy of Sciences.

[24]  Katherine S. Rojas,et al.  Identification of mTORC2 as a Necessary Component of HRG/ErbB2-Dependent Cellular Transformation , 2014, Molecular Cancer Research.

[25]  J. Gray,et al.  Therapeutic siRNA for drug-resistant HER2-positive breast cancer , 2016, Oncotarget.

[26]  G. Semenza,et al.  Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity , 2008, Molecular Cancer Therapeutics.

[27]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[28]  King-Jen Chang,et al.  Breast Cancer Cells Induce Cancer-Associated Fibroblasts to Secrete Hepatocyte Growth Factor to Enhance Breast Tumorigenesis , 2011, PloS one.

[29]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[30]  R. Pazdur,et al.  FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. , 2008, The oncologist.

[31]  Obi L. Griffith,et al.  Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer , 2015, PloS one.

[32]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[33]  K. Blackwell,et al.  Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. , 2009, The Lancet. Oncology.

[34]  S. Hilsenbeck,et al.  β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib , 2011, Breast Cancer Research.

[35]  O. Stål,et al.  Met and its ligand HGF are associated with clinical outcome in breast cancer , 2016, Oncotarget.

[36]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[37]  Sung-Bae Kim,et al.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. , 2014, The Lancet. Oncology.

[38]  M. Sliwkowski,et al.  A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. , 2008, Cancer research.

[39]  M. Matthay,et al.  Neuregulin-1-Human Epidermal Receptor-2 Signaling Is a Central Regulator of Pulmonary Epithelial Permeability and Acute Lung Injury* , 2011, The Journal of Biological Chemistry.

[40]  A. Aplin,et al.  Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling in Mutant BRAF Melanoma* , 2015, The Journal of Biological Chemistry.

[41]  Mark A. LaBarge,et al.  Fabrication and use of microenvironment microarrays (MEArrays). , 2012, Journal of visualized experiments : JoVE.

[42]  R. Carano,et al.  Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non–Small Cell Lung Cancer , 2013, Science Translational Medicine.

[43]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[44]  Kevan M. Shokat,et al.  Overcoming Resistance to HER2 Inhibitors Through State-Specific Kinase Binding , 2016, Nature chemical biology.

[45]  K. Matsumoto,et al.  Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis. , 1997, Blood.

[46]  N. LeBrasseur,et al.  Serum Neuregulin-1β as a Biomarker of Cardiovascular Fitness , 2009 .

[47]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[48]  M. Beckmann,et al.  HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer , 2013, Breast Care.

[49]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[50]  M. Sliwkowski,et al.  Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.

[51]  R. Nahta,et al.  P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer. , 2013, Current medicinal chemistry.

[52]  J. Abraham,et al.  Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor. , 2016, Clinical breast cancer.

[53]  Robert Langer,et al.  An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors , 2015, Science Translational Medicine.

[54]  M. Siegmann,et al.  Multiple phosphorylation of ribosomal protein S6 during transition of quiescent 3T3 cells into early G1, and cellular compartmentalization of the phosphate donor. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Paul J. Harrison,et al.  Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain , 2004, Neuroscience.

[56]  Mina J Bissell,et al.  Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. , 2008, Seminars in cancer biology.

[57]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[58]  C. Miller,et al.  The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation , 2017, Science Translational Medicine.

[59]  T. Kanda,et al.  Histone–GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells , 1998, Current Biology.